Trials / Recruiting
RecruitingNCT06795009
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Phase I/IB Study of Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanzalintinib | Taken by mouth. |
| DRUG | Paclitaxel | 175 mg\^m2 intravenous over 3 hours. |
Timeline
- Start date
- 2025-10-17
- Primary completion
- 2029-11-30
- Completion
- 2035-04-30
- First posted
- 2025-01-27
- Last updated
- 2025-12-11
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06795009. Inclusion in this directory is not an endorsement.